Jump to content

Inflammasome

From Wikipedia, the free encyclopedia
(Redirected from NLRP3 inflammasome)

Inflammasomes are cytosolic multiprotein complexes of the innate immune system responsible for the activation of inflammatory responses and cell death.[1][2] They are formed as a result of specific  cytosolic pattern recognition receptors (PRRs) sensing microbe-derived pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs) from the host cell, or homeostatic disruptions.[1][2][3] Activation and assembly of the inflammasome promotes the activation of caspase-1, which then proteolytically cleaves pro-inflammatory cytokines, interleukin 1β (IL-1β) and interleukin 18 (IL-18), as well as the pore-forming molecule gasdermin D (GSDMD).[2][3][4] The N-terminal GSDMD fragment resulting from this cleavage induces a pro-inflammatory form of programmed cell death distinct from apoptosis, referred to as pyroptosis, which is responsible for the release of mature cytokines.[2][5] Additionally, inflammasomes can act as integral components of larger cell death-inducing complexes called PANoptosomes, which drive another distinct form of pro-inflammatory cell death called PANoptosis.[4][6]

The germline-encoded PRRs that drive inflammasome formation consist of NLRs (nucleotide-binding oligomerization domain and leucine-rich repeat-containing receptors), AIM2 (absent in melanoma 2), IFI16 (IFN-inducible protein 16), and pyrin.[2][7] Through their caspase activation and recruitment domain (CARD) or pyrin domain (PYD), the inflammasome receptors interact with the adaptor protein called apoptosis-associated speck like protein containing a CARD (also known as ASC or Pycard), which then recruits pro-caspase-1 via its CARD domain to activate inflammatory signaling and pyroptotic cell death.[2][8] Notably, the PYD of the adaptor protein ASC has been demonstrated to function as a prion-like domain, forming a self-perpetuating polymer when activated.[9] In addition to inflammasomes activating caspase-1, several studies also described non-canonical inflammasome complexes that act independent of caspase-1. In mice, the non-canonical inflammasome is activated by direct sensing of cytosolic bacterial lipopolysaccharide (LPS) by caspase-11, which subsequently induces pyroptotic cell death.[doi:10.1038/nri.2016.58] In human cells, the corresponding caspases of the non-canonical inflammasome are caspase 4 and caspase 5.[10][11][12][13][14]

Traditionally, inflammasomes have mainly been studied in professional innate immune cells, such as macrophages. However, recent studies indicate high levels of inflammasome component expression in epithelial barrier tissues, where they have been demonstrated to serve as an important first line of defense.[15] Moreover, the dysregulation of inflammasome activation can contribute to the pathology of several major diseases, including cancer, autoimmune disorders, inflammatory conditions, metabolic disorders, and neurodegenerative diseases.[2][16]

Discovery

[edit]

The inflammasome was discovered by the team of Jürg Tschopp, at the University of Lausanne, in 2002.[17][18] In 2002, it was first reported by Martinon et al.[17] that NLRP1 (NLR family PYD-containing 1) could assemble and oligomerize into a structure in vitro, which activated the caspase-1 cascade, thereby leading to the production of pro-inflammatory cytokines, including IL-1β and IL-18. This NLRP1 multi-molecular complex was dubbed the ‘inflammasome’, generating significant interest in the following years. During that time, several other inflammasomes were discovered, two of which are also driven by NLRs—NLRP3 (NLR family PYD-containing 3) and NLRC4 (NLR family CARD-containing 4).[18] The physiological relevance of the inflammasome was identified in 2006, when three teams defined the inflammasome's role in diseases such as infection, exposure to toxins, gout, and type 2 diabetes.[19][20][21][18] Several PAMPs and DAMPs, including bacterial RNA and imidazoquinolines, viral DNA, muramyl dipeptide (MDP), asbestos, and silica, were found to induce an inflammasome response.[22] Additional links were also found between metabolic syndrome and NLRP3, one of the inflammasome sensors.[18] These findings paved the way for present-day studies in the fields of innate immunity and cell death, where disease mechanisms and treatments are being investigated in relation to inflammasome assembly and activation.[18]

Inflammasomes can also be formed by PRRs other than NLR proteins. In 2009, Hornung et al. identified a PYHIN (pyrin and HIN domain-containing protein) known as AIM2 that assembles an inflammasome in response to foreign cytoplasmic double-stranded DNA (dsDNA),[23] which several other groups also confirmed in back-to-back studies with Hornung et al.[24][25][26] Since then, other non-NLR inflammasome sensors have also been identified.

Inflammation activation

[edit]

Assembly of the inflammasome and the resulting inflammatory signaling cascade involve a well-orchestrated mechanism comprising upstream sensors, adapters, and downstream effectors. Inflammasomes play a crucial role in innate immunity via PRR activation in response to an array of stimuli, such as infectious triggers (including bacteria, fungi, viruses, and parasites) and sterile triggers (including ion flux, mitochondrial dysfunction, ROS, and metabolic factors).[26][27]

Canonical inflammasomes are assembled by the NLRs (including NLRP1, NLRP3, NLRC4), AIM2, and pyrin[2] by recruiting pro-caspase-1 (the precursor molecule of caspase-1), with or without the ASC adaptor.[7][ In its complete state, the inflammasome appositions together many p45 pro-caspase-1 molecules, inducing their autocatalytic cleavage into p20 and p10 subunits. Caspase-1 then assembles into its active form, which consists of two heterodimers, including a p20 and p10 subunit each.[28]

Caspase-1 activation facilitates the release of the inflammatory cytokines IL-1β and IL-18. The cleavage of GSDMD is also initiated by active caspase-1, which results in pyroptosis (where the cell releases its cytoplasmic content to induce pro-inflammatory signaling). The released IL-1β and IL-18 following inflammasome activation induce interferon gamma (IFN-γ) secretion and natural killer cell activation,[29] inactivation of IL-33,[30] DNA fragmentation and cell pore formation,[31] inhibition of glycolytic enzymes,[32] activation of lipid biosynthesis,[33] and secretion of tissue-repair mediators such as pro-IL-1α.[34]  While NLRP1, NLRP3, NLRC4, AIM2, and pyrin are the most well-characterized sensors, IFI16, NLRP6, NLRP7, NLRP9b, NLRP10, NLRP12, and CARD8 also play important roles in inflammasome activation and signaling.

The non-canonical inflammasomes are assembled by caspase-11 (caspases−4 and -5 in humans). Caspases-11, -4 or -5 can then cleave GSDMD to induce pyroptosis or activation of the NLRP3 inflammasome complex.[35][14]

Inflammasome family

[edit]

The inflammasome sensors are categorized based on their structural characteristics into NLRs, ALRs, and pyrin. These receptors possess the ability to form inflammasomes and trigger caspase-1 activation. The NLR family can be classified either as NLRP or NLRC subfamilies depending on whether the N terminus contains a PYD or CARD, respectively. Specific proteins, such as NLRP1, NLRP3, and NLRC4, have been mainly recognized as NLRs that can assemble an inflammasomes, whereas others, such as NLRP6, NLRP12, and so on are regarded as context-dependent inflammasome sensors.[36]

NLR-based inflammasomes

[edit]

NLRP1, NLRP3, and NLRC4 are members of the NLR family and are characterized by two common features: the first is a nucleotide-binding oligomerization domain (NOD), which can bind ribonucleotide-phosphates (rNTP) and plays an important role in self-oligomerization.[37] The second is a C-terminal leucine-rich repeat (LRR), which can function as a ligand-recognition domain for other receptors (e.g. TLR) or microbial ligands in some cases.[5] NLRP1 is most highly expressed in epithelial barriers (including keratinocytes and bronchial epithelial cells); NLRP3 in myeloid cells (monocytes, macrophages, neutrophils, and dendritic cells); and NLRC4 in myeloid cells, astrocytes, and intestinal epithelial cells, among other cell types.[38][39][40] 

NLRP1 inflammasome

[edit]

The NLRP1 inflammasome was the first to be identified and studied extensively. In addition to NOD and LRR, the NLRP1 structure consists of a PYD at its N-terminal, a FIIND motif, and a CARD at its C-terminus, which helps distinguish it from the other inflammasome sensors.[2][41] While there is only one NLRP1 protein present in humans, there are three paralogs of Nlrp1 (NLRP1A, B, C) in the mouse genome, and the murine NLRP1B inflammasome can be formed by recruitment of caspase-1 either with or without ASC.[42] The recruitment and cleavage of pro-caspase-1 can then activate the downstream caspase-1-mediated pathways.[27]

Various stimuli have been linked to the activation of NLRP1.[43][27] NLRP1B in mice and NLRP2 in rats were found to be responsive to Bacillus anthracis lethal toxin.[2] The B. anthracis lethal factor proteolytically cleaves NLRP1B, resulting in ubiquitination of the receptor and degradation by the proteasome. This degradation generates a clipped C-terminal fragment, which subsequently binds to the rest of the protein in a non-covalent manner. During this step, the CARD on the C-terminal fragment becomes accessible for inflammasome assembly.[15] So far, this activation mechanism based on proteasome degradation is unique to this inflammasome.[15] NLRP1 activity is regulated by the anti-apoptotic proteins Bcl-2 and Bcl-x(L) which, in resting cells, associate with and inhibit NLRP1 activity.[44]

NLRP3 inflammasome

[edit]

NLRP3 is one of the most well-researched inflammasome sensors. The NLRP3 structure consists of PYD along with the NOD and LRR domains. It triggers caspase-1 activation by using PYD to recruit ASC and form a single oligomer in each cell, which includes seven NLRP3 molecules. NLRP3 has been recognized as the largest inflammasome, with a diameter of around 2 um.[45][46]

NLRP3 oligomerization is activated by a large number of diverse stimuli, such as DAMPs, including crystalline matter (e.g., monosodium urate (MSU) crystals), alum, asbestos, calcium influx, mitochondrial reactive oxygen species (ROS), and extracellular ATP.[2][47] The NLRP3 inflammasome is additionally known to assemble in response to PAMPs from pathogens, including viruses, such as influenza A,[48] bacteria, such as Neisseria gonorrhoeae,[30] bacterial toxins like nigericin and maitotoxin,[1] and fungi, such as Aspergillus fumigatus.[49]

Many NLRP3 activators induce cytosolic potassium efflux from cells, and a sufficiently low cytosolic potassium concentration can trigger NLRP3 activation in the absence of other stimuli.[2] However, NLRP3 inflammasome activation can also occur independent of the potassium efflux by employing small molecules that target mitochondria or through other mechanisms.[50][7] Additionally, cholesterol and MSU crystals activate the NLRP3 inflammasome, leading to increased IL-1β-production.[20][51]  This process is thought to be abrogated in atherosclerosis and gout, where these crystals accumulate within the cell. It has also been established that inorganic particles like titanium dioxide, silicon dioxide, and asbestos can activate the inflammasome.[52] While the activation of the NLRP3 inflammasome leads to a potent inflammatory response to various pathogens and stress signals,[27] it has also been reported that NLRP3 inflammasome activation may play a role in sleep regulation.[53] Additionally, recent studies indicate that NLRP3 inflammasome-mediated neuroinflammation is involved in secondary brain injury following intracerebral hemorrhage.[54]

The NLRP3 inflammasome is also an essential component of several PANoptosomes, including the ZBP1-, RIPK1-, and NLRP12-PANoptosome.[55]

NAIP/NLRC4 inflammasome

[edit]

NLRC4 is the only member of the NLRC family currently known to assemble an inflammasome. NLRC4 consists of a CARD along with the NOD and LRR domains to directly recruit the adaptor protein ASC, or pro-caspase-1.[56] The NLR family apoptosis inhibitory proteins, or NAIPs, are crucial for serving as a sensor to facilitate the activation of the NLRC4 inflammasome.[57]

The NAIP/NLRC4 inflammasome is involved in host defense against several pathogens.[58][59] In mice, NAIPs are activated by binding to the bacterial PAMPs in the cytosol, which are provided by the rod (NAIP2) and needle (NAIP1) components of the bacterial type-3 secretion system (T3SS), as well as flagellin, the molecular building block of flagella (NAIP5 and -6). Humans have a single NAIP that specifically responds to the needle component.[60][2] Following ligand binding, NAIPs interact with NLRC4 to initiate the assembly of the NLRC4 inflammasome, which then recruits and activates pro-caspase-1 via its CARD.[60] Experimental evidence demonstrates that palmitate may induce the NLRC4 inflammasome in the absence of bacteria.[58]

The NLRC4 inflammasome is a well-documented epithelial inflammasome that is crucial in limiting intraepithelial bacterial populations during the early stages of enterobacterial infections such as Salmonella and Citrobacter rodentium.[61][62] Intracellular bacteria activate the inflammasome, resulting in the targeted expulsion of infected epithelial cells from the epithelium to reduce the bacterial load. This process, known as epithelial cell extrusion, occurs without compromising the integrity of the epithelial barrier. Furthermore, the NLRC4 inflammasome was found to reduce tumor load in a mouse model of colorectal carcinoma (CRC) by triggering the elimination of tumor-initiating cells.[61][62]

Non-NLR-based inflammasomes

[edit]

AIM2, pyrin, IFI16, and others are non-NLR members that form inflammasomes.

AIM2 inflammasome

[edit]

The AIM2 inflammasome senses cytosolic dsDNA and plays a crucial role in host defense against DNA viruses and intracellular bacterial infections.[24][23] AIM2 consists of an N-terminal PYD and a C-terminal HIN domain. Both domains interact to maintain the molecule in an auto-inhibited state. Binding of dsDNA results in the release of auto-inhibition, which leads to the formation of AIM2 oligomers.[63] These oligomers then recruit the adaptor ASC through contacts between their PYDs, which is required for the AIM2 inflammasome assembly and activation.[63] As a result, pro-caspase-1 is recruited to the inflammasome complex, triggering a robust innate immune response and pyroptotic cell death.[64]

AIM2 is mainly expressed in intestinal and lymphoid tissue and in cell types such as B-cells, plasma cells, late spermatids, early spermatids, and Schwann cells.[65] AIM2 plays an essential role in inflammation, autoimmune diseases, cancer, and host defense against infections via inflammasome-dependent and -independent pathways.[66][67][64] In addition, the AIM2 inflammasome also acts as an integral components of the AIM2-PANoptosome complex with pyrin and ZBP1 to promote PANoptosis and host defense in response to F. novicida and HSV1.[68]

IFI16 inflammasome

[edit]

Like AIM2, IFI16 (IFN-inducible protein 16) belongs to the PYHIN family. IFI16 in humans, and the mouse orthologue IFI204, plays an important role in regulating the production of IFN upon bacterial and viral infections.[2][69] Unlike AIM2, IFI16 is a nuclear DNA sensor.[15] Upon sensing viral DNAs, IFI16 recruits caspase-1 by interacting with ASC, resulting in death of CD4+ T cells in response to HIV infection.[70]

Pyrin inflammasome

[edit]

Pyrin is an innate immune sensor that coordinates the assembly of the inflammasome in response to bacterial toxins as well as effector proteins via the detection of pathogen-driven alterations in cytoskeleton dynamics.[2] Pyrin expression is specific to the cells of the innate immune system, including granulocytes, eosinophils, monocytes, and dendritic cells.[71] Pyrin particularly detects the inactivation of the Rho GTPase RHOA by bacterial factors.[2] Upon RHOA inactivation, pyrin engages in a homotypic association with ASC via its N-terminal PYD, leading to the formation of micrometer-sized assemblies known as ASC specks by oligomerization, finally resulting in the activation of caspase-1. This results in the release of inflammatory cytokines, including IL-1β.[72][73]

Non-canonical inflammasomes

[edit]

The non-canonical inflammasomes are independent of caspase-1 and activate caspase-11 in mice, and caspase-4 and -5 in humans[2] upon sensing intracellular LPS, a prototypic PAMP that plays a significant role in sepsis and septic shock. This initiates pyroptotic cell death by the cleavage of the pore-forming protein GSDMD[15] leading to the secondary activation of the canonical NLRP3 inflammasome and cytokine release.[74][2][35][14]

The primary function of the non-canonical inflammasome is to aid in the defense against Gram-negative bacteria,[11] as well as eliminate pathogens and alert neighboring cells by releasing alarmins, DAMPs, and canonical NLRP3 inflammasome-dependent cytokines.[75] However, the effects of canonical and non-canonical inflammasome activation are similar.

In addition to LPS, there is evidence suggesting that certain other triggers can alternatively activate the non-canonical inflammasome (via caspase-11).[74] The non-canonical inflammasome plays key roles in endotoxemia and sepsis, making its components valuable targets for clinical intervention.[74][76][77]

Role in health

[edit]

Role in innate immunity

[edit]

Inflammasomes are crucial components of the innate immune system that initiate inflammatory responses and regulate host defenses by activating and releasing pro-inflammatory cytokines and inducing pyroptosis.[2] Inflammasomes and their components are also involved in executing PANoptosis, which is another form of innate immune inflammatory lytic cell death.[78]

In addition to specialized innate immune cells such as macrophages, several studies have examined various epithelial inflammasomes and emphasized their role in immune defense.[61] Epithelia not only act as a physical barrier but also initiate a defensive response upon initial contact with pathogens. Various inflammasome components were found to be ex[62]pressed in various epithelial tissues.[79][61] The expression of innate immune components at epithelial barriers facilitates pathogen detection, as the expression of virulence factors and the exposure of PAMPs is required for breaching these barriers upon pathogen invasion. However, these factors may be downregulated when the pathogen interacts with professional immune cells at later stages of the infection.[62] Research on epithelial inflammasomes has been largely focused on the intestinal mucosa. Inflammasomes have also been identified in other tissues, such as the urinary bladder epithelium.[62]

Murine caspase-11 is mainly expressed in macrophages, while human caspase-4 is highly expressed in intestinal epithelial cells.[62] Human epithelial cells exhibit caspase-4-dependent, caspase-1-independent cell death and extrusion when infected with enteropathogens such as Salmonella, Shigella flexneri, or Escherichia coli, similar to the observations for the epithelial NAIP/NLRC4 inflammasome.[62] Furthermore, IL-18 production can be triggered by cytosolic LPS in epithelial cells.[62]

The activation of epithelial inflammasomes in response to invading pathogens has significant cell-autonomous effects on the infected cell as well as on its communication with other cell types on a local and global level.[62] The downstream consequences of inflammasome activation can be categorized into three groups: (1) epithelial cell death, (2) release of soluble pro-inflammatory molecules, and (3) effector cell recruitment and activation.[62] In addition, epithelial inflammasome activation induces contraction of epithelial layers[80] and maintains integrity during later stages of infection.[81]

The activation of the inflammasome in the epithelial barrier needs to be precisely balanced  to eliminate infected cells while also preserving the integrity of the barrier.[62] Inflammasome activation can trigger epithelial cell death in a direct, cell-autonomous manner, as well as local recruitment of other death-inducing cell types, or inflammation, resulting in enhanced epithelial turnover that eliminates both infected and uninfected cells. Neutrophils, along with NK and mast cells, are crucial innate immune effector cells that infiltrate infected tissue after pathogens breach epithelial barriers. They immobilize and eliminate pathogens, secrete inflammatory mediators like IFN-γ and IL-22, and eliminate microorganisms trapped within pyroptotic macrophages.[62]

Inflammasome-dependent IL-1β and IL-18 release recruit effector cells, orchestrating the innate immune response. IL-1β production is modest by intestinal epithelial cells, while IL-18 secreted can induce IFN-γ production by several cell types.[2][62] IL-18, derived from the inflammasome, aids in the early stages of innate immune responses by recruiting natural killer cells, stimulating their effector functions, and secreting IFN-γ to recruit other inflammatory cells.

A study on urinary bladder epithelium infection found high levels of IL-1β secretion by epithelial cells, influenced by the NLRP3 inflammasome and caspase-1, which recruits mast cells and induces lytic cell death.[62]

Role in disease

[edit]

Inflammasomes play significant roles in the development or progression of pathologies that have a substantial impact on public health, such as inflammatory conditions (liver diseases, inflammatory bowel diseases, and rheumatoid arthritis), metabolic disorders (obesity, type 2 diabetes, and atherosclerosis), cardiovascular diseases (ischemic and non-ischemic heart disease), neurological disorders (Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and other neurological disorders), and cancer.[82][83][84]

The gain-of-function mutations in inflammasome components are also known to cause cryopyrin-associated periodic syndrome (CAPS), a group of congenital diseases characterized by IL-1β-mediated systemic inflammation. However, in certain circumstances, inflammasome signaling is beneficial in infections and can also impede tumor growth.[83][85][86][87] The tumor-suppressive effect of the NLRP3,[88][89] AIM2,[90][91] and NLRC4[92] inflammasomes is widely recognized.

Clinical significance

[edit]

Several agents, including anakinra, canakinumab, rilonacept, and IL-18–binding protein, have been developed to treat autoinflammatory diseases like CAPS and other conditions where inflammasomes can be hyperactivated. These agents target the downstream effectors of inflammasome activation, namely IL-1β and IL-18.[16][93][94] The involvement of the NLRP3 inflammasome specifically in several diseases has accelerated the discovery of efficient NLRP3 inhibitors.[95][96]. However, despite these advances, no specific NLR inhibitors for clinical use have been approved by the FDA to date.

References

[edit]
  1. ^ a b c Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, et al. (July 2004). "Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf". Nature. 430 (6996): 213–218. Bibcode:2004Natur.430..213M. doi:10.1038/nature02664. PMID 15190255. S2CID 4317409.
  2. ^ a b c d e f g h i j k l m n o p q r s t Broz P, Dixit VM (July 2016). "Inflammasomes: mechanism of assembly, regulation and signalling". Nature Reviews. Immunology. 16 (7): 407–420. doi:10.1038/nri.2016.58. PMID 27291964. S2CID 32414010.
  3. ^ a b Broz, Petr; Monack, Denise M. (August 2013). "Newly described pattern recognition receptors team up against intracellular pathogens". Nature Reviews Immunology. 13 (8): 551–565. doi:10.1038/nri3479. ISSN 1474-1733. PMID 23846113.
  4. ^ a b Martinon, Fabio; Burns, Kimberly; Tschopp, Jürg (August 2002). "The Inflammasome". Molecular Cell. 10 (2): 417–426. doi:10.1016/S1097-2765(02)00599-3. PMID 12191486.
  5. ^ a b Fu, Jianing; Schroder, Kate; Wu, Hao (2024-02-19). "Mechanistic insights from inflammasome structures". Nature Reviews Immunology. 24 (7): 518–535. doi:10.1038/s41577-024-00995-w. ISSN 1474-1733. PMC 11216901. PMID 38374299.
  6. ^ Pandian, Nagakannan; Kanneganti, Thirumala-Devi (2022-11-01). "PANoptosis: A Unique Innate Immune Inflammatory Cell Death Modality". The Journal of Immunology. 209 (9): 1625–1633. doi:10.4049/jimmunol.2200508. ISSN 0022-1767. PMC 9586465. PMID 36253067.
  7. ^ a b c Barnett, Katherine C.; Li, Sirui; Liang, Kaixin; Ting, Jenny P.-Y. (May 2023). "A 360° view of the inflammasome: Mechanisms of activation, cell death, and diseases". Cell. 186 (11): 2288–2312. doi:10.1016/j.cell.2023.04.025. PMC 10228754. PMID 37236155.
  8. ^ Kanneganti TD, Lamkanfi M, Núñez G (October 2007). "Intracellular NOD-like receptors in host defense and disease". Immunity. 27 (4): 549–559. doi:10.1016/j.immuni.2007.10.002. PMID 17967410.
  9. ^ Cai X, Chen J, Xu H, Liu S, Jiang QX, Halfmann R, Chen ZJ (March 2014). "Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation". Cell. 156 (6): 1207–1222. doi:10.1016/j.cell.2014.01.063. PMC 4034535. PMID 24630723.
  10. ^ Kayagaki, Nobuhiko; Warming, Søren; Lamkanfi, Mohamed; Walle, Lieselotte Vande; Louie, Salina; Dong, Jennifer; Newton, Kim; Qu, Yan; Liu, Jinfeng; Heldens, Sherry; Zhang, Juan; Lee, Wyne P.; Roose-Girma, Merone; Dixit, Vishva M. (November 2011). "Non-canonical inflammasome activation targets caspase-11". Nature. 479 (7371): 117–121. Bibcode:2011Natur.479..117K. doi:10.1038/nature10558. ISSN 0028-0836. PMID 22002608.
  11. ^ a b Aachoui, Youssef; Leaf, Irina A.; Hagar, Jon A.; Fontana, Mary F.; Campos, Cristine G.; Zak, Daniel E.; Tan, Michael H.; Cotter, Peggy A.; Vance, Russell E.; Aderem, Alan; Miao, Edward A. (2013-02-22). "Caspase-11 Protects Against Bacteria That Escape the Vacuole". Science. 339 (6122): 975–978. Bibcode:2013Sci...339..975A. doi:10.1126/science.1230751. ISSN 0036-8075. PMC 3697099. PMID 23348507.
  12. ^ Casson, Cierra N.; Copenhaver, Alan M.; Zwack, Erin E.; Nguyen, Hieu T.; Strowig, Till; Javdan, Bahar; Bradley, William P.; Fung, Thomas C.; Flavell, Richard A.; Brodsky, Igor E.; Shin, Sunny (2013-06-06). Isberg, Ralph R. (ed.). "Caspase-11 Activation in Response to Bacterial Secretion Systems that Access the Host Cytosol". PLOS Pathogens. 9 (6): e1003400. doi:10.1371/journal.ppat.1003400. ISSN 1553-7374. PMC 3675167. PMID 23762026.
  13. ^ Shi, Jianjin; Zhao, Yue; Wang, Yupeng; Gao, Wenqing; Ding, Jingjin; Li, Peng; Hu, Liyan; Shao, Feng (October 2014). "Inflammatory caspases are innate immune receptors for intracellular LPS". Nature. 514 (7521): 187–192. Bibcode:2014Natur.514..187S. doi:10.1038/nature13683. ISSN 0028-0836. PMID 25119034.
  14. ^ a b c Kayagaki, Nobuhiko; Stowe, Irma B.; Lee, Bettina L.; O’Rourke, Karen; Anderson, Keith; Warming, Søren; Cuellar, Trinna; Haley, Benjamin; Roose-Girma, Merone; Phung, Qui T.; Liu, Peter S.; Lill, Jennie R.; Li, Hong; Wu, Jiansheng; Kummerfeld, Sarah (2015-10-29). "Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling". Nature. 526 (7575): 666–671. Bibcode:2015Natur.526..666K. doi:10.1038/nature15541. ISSN 0028-0836. PMID 26375259.
  15. ^ a b c d e Winsor N, Krustev C, Bruce J, Philpott DJ, Girardin SE (November 2019). "Canonical and noncanonical inflammasomes in intestinal epithelial cells". Cellular Microbiology. 21 (11): e13079. doi:10.1111/cmi.13079. PMID 31265745. S2CID 195786609.
  16. ^ a b Guo, Haitao; Callaway, Justin B; Ting, Jenny P-Y (July 2015). "Inflammasomes: mechanism of action, role in disease, and therapeutics". Nature Medicine. 21 (7): 677–687. doi:10.1038/nm.3893. ISSN 1078-8956. PMC 4519035. PMID 26121197.
  17. ^ a b Martinon F, Burns K, Tschopp J (August 2002). "The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta". Molecular Cell. 10 (2): 417–426. doi:10.1016/S1097-2765(02)00599-3. PMID 12191486.
  18. ^ a b c d e Dagenais M, Skeldon A, Saleh M (January 2012). "The inflammasome: in memory of Dr. Jurg Tschopp". Cell Death and Differentiation. 19 (1): 5–12. doi:10.1038/cdd.2011.159. PMC 3252823. PMID 22075986.
  19. ^ Mariathasan, Sanjeev; Weiss, David S.; Newton, Kim; McBride, Jacqueline; O'Rourke, Karen; Roose-Girma, Meron; Lee, Wyne P.; Weinrauch, Yvette; Monack, Denise M.; Dixit, Vishva M. (March 2006). "Cryopyrin activates the inflammasome in response to toxins and ATP". Nature. 440 (7081): 228–232. Bibcode:2006Natur.440..228M. doi:10.1038/nature04515. ISSN 0028-0836. PMID 16407890.
  20. ^ a b Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (March 2006). "Gout-associated uric acid crystals activate the NALP3 inflammasome". Nature. 440 (7081): 237–241. Bibcode:2006Natur.440..237M. doi:10.1038/nature04516. PMID 16407889.
  21. ^ Kanneganti, Thirumala-Devi; Özören, Nesrin; Body-Malapel, Mathilde; Amer, Amal; Park, Jong-Hwan; Franchi, Luigi; Whitfield, Joel; Barchet, Winfried; Colonna, Marco; Vandenabeele, Peter; Bertin, John; Coyle, Anthony; Grant, Ethan P.; Akira, Shizuo; Núñez, Gabriel (March 2006). "Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3". Nature. 440 (7081): 233–236. Bibcode:2006Natur.440..233K. doi:10.1038/nature04517. hdl:2027.42/62569. ISSN 0028-0836. PMID 16407888.
  22. ^ Khare, Sonal; Luc, Nancy; Dorfleutner, Andrea; Stehlik, Christian (2010). "Inflammasomes and Their Activation". Critical Reviews in Immunology. 30 (5): 463–487. doi:10.1615/CritRevImmunol.v30.i5.50. ISSN 2162-6472. PMC 3086048. PMID 21083527.
  23. ^ a b Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. (March 2009). "AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC". Nature. 458 (7237): 514–518. Bibcode:2009Natur.458..514H. doi:10.1038/nature07725. PMC 2726264. PMID 19158675.
  24. ^ a b Roberts TL, Idris A, Dunn JA, Kelly GM, Burnton CM, Hodgson S, et al. (February 2009). "HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA". Science. 323 (5917): 1057–1060. Bibcode:2009Sci...323.1057R. doi:10.1126/science.1169841. PMID 19131592. S2CID 43712804.
  25. ^ Bürckstümmer T, Baumann C, Blüml S, Dixit E, Dürnberger G, Jahn H, et al. (March 2009). "An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome". Nature Immunology. 10 (3): 266–272. doi:10.1038/ni.1702. PMID 19158679. S2CID 5597950.
  26. ^ a b Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES (March 2009). "AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA". Nature. 458 (7237): 509–513. Bibcode:2009Natur.458..509F. doi:10.1038/nature07710. PMC 2862225. PMID 19158676.
  27. ^ a b c d Zheng, Danping; Liwinski, Timur; Elinav, Eran (2020-06-09). "Inflammasome activation and regulation: toward a better understanding of complex mechanisms". Cell Discovery. 6 (1): 36. doi:10.1038/s41421-020-0167-x. ISSN 2056-5968. PMC 7280307. PMID 32550001.
  28. ^ Yamin, Ting-Ting; Ayala, Julia M.; Miller, Douglas K. (May 1996). "Activation of the Native 45-kDa Precursor Form of Interleukin-1-converting Enzyme". Journal of Biological Chemistry. 271 (22): 13273–13282. doi:10.1074/jbc.271.22.13273. PMID 8662843.
  29. ^ Gu, Yong; Kuida, Keisuke; Tsutsui, Hiroko; Ku, George; Hsiao, Kathy; Fleming, Mark A.; Hayashi, Nobuki; Higashino, Kazuya; Okamura, Haruki; Nakanishi, Kenji; Kurimoto, Masashi; Tanimoto, Tadao; Flavell, Richard A.; Sato, Vicki; Harding, Matthew W. (1997-01-10). "Activation of Interferon-γ Inducing Factor Mediated by Interleukin-1β Converting Enzyme". Science. 275 (5297): 206–209. doi:10.1126/science.275.5297.206. ISSN 0036-8075. PMID 8999548.
  30. ^ Cayrol, Corinne; Girard, Jean-Philippe (2009-06-02). "The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1". Proceedings of the National Academy of Sciences. 106 (22): 9021–9026. Bibcode:2009PNAS..106.9021C. doi:10.1073/pnas.0812690106. ISSN 0027-8424. PMC 2690027. PMID 19439663.
  31. ^ Fink, Susan L.; Cookson, Brad T. (November 2006). "Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages". Cellular Microbiology. 8 (11): 1812–1825. doi:10.1111/j.1462-5822.2006.00751.x. ISSN 1462-5814. PMID 16824040.
  32. ^ Shao, Wei; Yeretssian, Garabet; Doiron, Karine; Hussain, Sabah N.; Saleh, Maya (December 2007). "The Caspase-1 Digestome Identifies the Glycolysis Pathway as a Target during Infection and Septic Shock". Journal of Biological Chemistry. 282 (50): 36321–36329. doi:10.1074/jbc.M708182200. PMID 17959595.
  33. ^ Gurcel, Laure; Abrami, Laurence; Girardin, Stephen; Tschopp, Jurg; van der Goot, F. Gisou (September 2006). "Caspase-1 Activation of Lipid Metabolic Pathways in Response to Bacterial Pore-Forming Toxins Promotes Cell Survival". Cell. 126 (6): 1135–1145. doi:10.1016/j.cell.2006.07.033. PMID 16990137.
  34. ^ Keller, Martin; Rüegg, Andreas; Werner, Sabine; Beer, Hans-Dietmar (March 2008). "Active Caspase-1 Is a Regulator of Unconventional Protein Secretion". Cell. 132 (5): 818–831. doi:10.1016/j.cell.2007.12.040. PMID 18329368.
  35. ^ a b Shi, Jianjin; Zhao, Yue; Wang, Kun; Shi, Xuyan; Wang, Yue; Huang, Huanwei; Zhuang, Yinghua; Cai, Tao; Wang, Fengchao; Shao, Feng (2015-10-29). "Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death". Nature. 526 (7575): 660–665. Bibcode:2015Natur.526..660S. doi:10.1038/nature15514. ISSN 0028-0836. PMID 26375003.
  36. ^ Sharma, Deepika; Kanneganti, Thirumala-Devi (2016-06-20). "The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation". Journal of Cell Biology. 213 (6): 617–629. doi:10.1083/jcb.201602089. ISSN 0021-9525. PMC 4915194. PMID 27325789.
  37. ^ Ye, Zhengmao; Lich, John D.; Moore, Chris B.; Duncan, Joseph A.; Williams, Kristi L.; Ting, Jenny P.-Y. (2008-03-01). "ATP Binding by Monarch-1/NLRP12 Is Critical for Its Inhibitory Function". Molecular and Cellular Biology. 28 (5): 1841–1850. doi:10.1128/MCB.01468-07. ISSN 1098-5549. PMC 2258772. PMID 18160710.
  38. ^ Jamilloux, Yvan; Pierini, Roberto; Querenet, Mathieu; Juruj, Carole; Fauchais, Anne-Laure; Jauberteau, Marie-Odile; Jarraud, Sophie; Lina, Gérard; Etienne, Jérôme; Roy, Craig R.; Henry, Thomas; Davoust, Nathalie; Ader, Florence (April 2013). "Inflammasome activation restricts Legionella pneumophila replication in primary microglial cells through flagellin detection". Glia. 61 (4): 539–549. doi:10.1002/glia.22454. ISSN 0894-1491. PMID 23355222.
  39. ^ Davis, Beckley K.; Wen, Haitao; Ting, Jenny P.-Y. (2011-04-23). "The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases". Annual Review of Immunology. 29 (1): 707–735. doi:10.1146/annurev-immunol-031210-101405. ISSN 0732-0582. PMC 4067317. PMID 21219188.
  40. ^ Chou, Wei-Chun; Jha, Sushmita; Linhoff, Michael W.; Ting, Jenny P.-Y. (October 2023). "The NLR gene family: from discovery to present day". Nature Reviews Immunology. 23 (10): 635–654. doi:10.1038/s41577-023-00849-x. ISSN 1474-1733. PMC 11171412. PMID 36973360.
  41. ^ Chavarría-Smith, Joseph; Vance, Russell E. (May 2015). "The NLRP 1 inflammasomes". Immunological Reviews. 265 (1): 22–34. doi:10.1111/imr.12283. ISSN 0105-2896. PMID 25879281.
  42. ^ Xu, Zhihao; Zhou, Ying; Liu, Muziying; Ma, Huan; Sun, Liangqi; Zahid, Ayesha; Chen, Yulei; Zhou, Rongbin; Cao, Minjie; Wu, Dabao; Zhao, Weidong; Li, Bofeng; Jin, Tengchuan (2021-01-11). "Homotypic CARD-CARD interaction is critical for the activation of NLRP1 inflammasome". Cell Death & Disease. 12 (1): 57. doi:10.1038/s41419-020-03342-8. ISSN 2041-4889. PMC 7801473. PMID 33431827.
  43. ^ Chen, Chen; Xu, Pinglong (2022-07-20). "Activation and Pharmacological Regulation of Inflammasomes". Biomolecules. 12 (7): 1005. doi:10.3390/biom12071005. ISSN 2218-273X. PMC 9313256. PMID 35883561.
  44. ^ Bruey JM, Bruey-Sedano N, Luciano F, Zhai D, Balpai R, Xu C, et al. (April 2007). "Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1". Cell. 129 (1): 45–56. doi:10.1016/j.cell.2007.01.045. PMID 17418785. S2CID 18347164.
  45. ^ Stutz A, Golenbock DT, Latz E (December 2009). "Inflammasomes: too big to miss". The Journal of Clinical Investigation. 119 (12): 3502–3511. doi:10.1172/JCI40599. PMC 2786809. PMID 19955661.
  46. ^ Kelley, Nathan; Jeltema, Devon; Duan, Yanhui; He, Yuan (2019-07-06). "The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation". International Journal of Molecular Sciences. 20 (13): 3328. doi:10.3390/ijms20133328. ISSN 1422-0067. PMC 6651423. PMID 31284572.
  47. ^ Crowley SM, Knodler LA, Vallance BA (2016). "Salmonella and the Inflammasome: Battle for Intracellular Dominance". In Backert S (ed.). Inflammasome Signaling and Bacterial Infections. Current Topics in Microbiology and Immunology. Vol. 397. Springer International Publishing. pp. 43–67. doi:10.1007/978-3-319-41171-2_3. ISBN 978-3-319-41170-5. PMID 27460804.
  48. ^ Kanneganti, Thirumala-Devi; Body-Malapel, Mathilde; Amer, Amal; Park, Jong-Hwan; Whitfield, Joel; Franchi, Luigi; Taraporewala, Zenobia F.; Miller, David; Patton, John T.; Inohara, Naohiro; Núñez, Gabriel (December 2006). "Critical Role for Cryopyrin/Nalp3 in Activation of Caspase-1 in Response to Viral Infection and Double-stranded RNA". Journal of Biological Chemistry. 281 (48): 36560–36568. doi:10.1074/jbc.M607594200. PMID 17008311.
  49. ^ Saïd-Sadier, Najwane; Padilla, Eduardo; Langsley, Gordon; Ojcius, David M. (2010-04-02). Unutmaz, Derya (ed.). "Aspergillus fumigatus Stimulates the NLRP3 Inflammasome through a Pathway Requiring ROS Production and the Syk Tyrosine Kinase". PLOS ONE. 5 (4): e10008. Bibcode:2010PLoSO...510008S. doi:10.1371/journal.pone.0010008. ISSN 1932-6203. PMC 2848854. PMID 20368800.
  50. ^ Groß, Christina J.; Mishra, Ritu; Schneider, Katharina S.; Médard, Guillaume; Wettmarshausen, Jennifer; Dittlein, Daniela C.; Shi, Hexin; Gorka, Oliver; Koenig, Paul-Albert; Fromm, Stephan; Magnani, Giovanni; Ćiković, Tamara; Hartjes, Lara; Smollich, Joachim; Robertson, Avril A.B. (October 2016). "K + Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria". Immunity. 45 (4): 761–773. doi:10.1016/j.immuni.2016.08.010. PMID 27692612.
  51. ^ Jamilloux Y, Sève P, Henry T (November 2014). "[Inflammasomes in human diseases]". La Revue de Médecine Interne. 35 (11): 730–741. doi:10.1016/j.revmed.2014.04.017. PMID 24907108.
  52. ^ Yazdi AS, Guarda G, Riteau N, Drexler SK, Tardivel A, Couillin I, Tschopp J (November 2010). "Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β". Proceedings of the National Academy of Sciences of the United States of America. 107 (45): 19449–19454. Bibcode:2010PNAS..10719449Y. doi:10.1073/pnas.1008155107. PMC 2984140. PMID 20974980.
  53. ^ Zielinski MR, Gerashchenko D, Karpova SA, Konanki V, McCarley RW, Sutterwala FS, et al. (May 2017). "The NLRP3 inflammasome modulates sleep and NREM sleep delta power induced by spontaneous wakefulness, sleep deprivation and lipopolysaccharide". Brain, Behavior, and Immunity. 62: 137–150. doi:10.1016/j.bbi.2017.01.012. PMC 5373953. PMID 28109896.
  54. ^ Ren H, Han R, Chen X, Liu X, Wan J, Wang L, et al. (September 2020). "Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update". Journal of Cerebral Blood Flow and Metabolism. 40 (9): 1752–1768. doi:10.1177/0271678X20923551. PMC 7446569. PMID 32423330. S2CID 218689863.
  55. ^ Pandeya, Ankit; Kanneganti, Thirumala-Devi (January 2024). "Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes". Trends in Molecular Medicine. 30 (1): 74–88. doi:10.1016/j.molmed.2023.10.001. PMC 10842719. PMID 37977994.
  56. ^ Romberg, Neil; Vogel, Tiphanie P.; Canna, Scott W. (December 2017). "NLRC4 inflammasomopathies". Current Opinion in Allergy & Clinical Immunology. 17 (6): 398–404. doi:10.1097/ACI.0000000000000396. ISSN 1528-4050. PMC 6070355. PMID 28957823.
  57. ^ Sundaram, Balamurugan; Kanneganti, Thirumala-Devi (2021-01-21). "Advances in Understanding Activation and Function of the NLRC4 Inflammasome". International Journal of Molecular Sciences. 22 (3): 1048. doi:10.3390/ijms22031048. ISSN 1422-0067. PMC 7864484. PMID 33494299.
  58. ^ a b Liu, Li; Chan, Christina (February 2014). "IPAF inflammasome is involved in interleukin-1β production from astrocytes, induced by palmitate; implications for Alzheimer's Disease". Neurobiology of Aging. 35 (2): 309–321. doi:10.1016/j.neurobiolaging.2013.08.016. PMC 3832124. PMID 24054992.
  59. ^ Vance, Russell E (February 2015). "The NAIP/NLRC4 inflammasomes". Current Opinion in Immunology. 32: 84–89. doi:10.1016/j.coi.2015.01.010. PMC 4336817. PMID 25621709.
  60. ^ a b Zhao, Yue; Shao, Feng (May 2015). "The NAIP – NLRC 4 inflammasome in innate immune detection of bacterial flagellin and type III secretion apparatus". Immunological Reviews. 265 (1): 85–102. doi:10.1111/imr.12293. ISSN 0105-2896. PMID 25879286.
  61. ^ a b c d Sellin ME, Maslowski KM, Maloy KJ, Hardt WD (August 2015). "Inflammasomes of the intestinal epithelium". Trends in Immunology. 36 (8): 442–450. doi:10.1016/j.it.2015.06.002. PMID 26166583.
  62. ^ a b c d e f g h i j k l m n Sellin ME, Müller AA, Hardt WD (January 2018). "Consequences of Epithelial Inflammasome Activation by Bacterial Pathogens". Journal of Molecular Biology. Mechanisms of Inflammasome Activation. 430 (2): 193–206. doi:10.1016/j.jmb.2017.03.031. PMID 28454742.
  63. ^ a b Lugrin, Jérôme; Martinon, Fabio (January 2018). "The AIM 2 inflammasome: Sensor of pathogens and cellular perturbations". Immunological Reviews. 281 (1): 99–114. doi:10.1111/imr.12618. ISSN 0105-2896. PMID 29247998.
  64. ^ a b Kumari, Puja; Russo, Ashley J.; Shivcharan, Sonia; Rathinam, Vijay A. (September 2020). "AIM2 in health and disease: Inflammasome and beyond". Immunological Reviews. 297 (1): 83–95. doi:10.1111/imr.12903. ISSN 0105-2896. PMC 7668394. PMID 32713036.
  65. ^ "AIM2 protein expression summary - The Human Protein Atlas". www.proteinatlas.org. Retrieved 2024-03-15.
  66. ^ Fukuda, Keitaro (2023-04-01). "Immune Regulation by Cytosolic DNA Sensors in the Tumor Microenvironment". Cancers. 15 (7): 2114. doi:10.3390/cancers15072114. ISSN 2072-6694. PMC 10093344. PMID 37046775.
  67. ^ Zhu, Huan; Zhao, Ming; Chang, Christopher; Chan, Vera; Lu, Qianjin; Wu, Haijing (September 2021). "The complex role of AIM2 in autoimmune diseases and cancers". Immunity, Inflammation and Disease. 9 (3): 649–665. doi:10.1002/iid3.443. ISSN 2050-4527. PMC 8342223. PMID 34014039.
  68. ^ Lee, SangJoon; Karki, Rajendra; Wang, Yaqiu; Nguyen, Lam Nhat; Kalathur, Ravi C.; Kanneganti, Thirumala-Devi (2021-09-16). "AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence". Nature. 597 (7876): 415–419. Bibcode:2021Natur.597..415L. doi:10.1038/s41586-021-03875-8. ISSN 0028-0836. PMC 8603942. PMID 34471287.
  69. ^ Zhao, Hua; Gonzalezgugel, Elena; Cheng, Lei; Richbourgh, Brendon; Nie, Lin; Liu, Chuanju (March 2015). "The roles of interferon-inducible p200 family members IFI16 and p204 in innate immune responses, cell differentiation and proliferation". Genes & Diseases. 2 (1): 46–56. doi:10.1016/j.gendis.2014.10.003. PMC 4372153. PMID 25815367.
  70. ^ Monroe, Kathryn M.; Yang, Zhiyuan; Johnson, Jeffrey R.; Geng, Xin; Doitsh, Gilad; Krogan, Nevan J.; Greene, Warner C. (2014-01-24). "IFI16 DNA Sensor Is Required for Death of Lymphoid CD4 T Cells Abortively Infected with HIV". Science. 343 (6169): 428–432. Bibcode:2014Sci...343..428M. doi:10.1126/science.1243640. ISSN 0036-8075. PMC 3976200. PMID 24356113.
  71. ^ Heilig, Rosalie; Broz, Petr (February 2018). "Function and mechanism of the pyrin inflammasome". European Journal of Immunology. 48 (2): 230–238. doi:10.1002/eji.201746947. ISSN 0014-2980. PMID 29148036.
  72. ^ Xu, Hao; Yang, Jieling; Gao, Wenqing; Li, Lin; Li, Peng; Zhang, Li; Gong, Yi-Nan; Peng, Xiaolan; Xi, Jianzhong Jeff; Chen, She; Wang, Fengchao; Shao, Feng (2014-09-11). "Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome". Nature. 513 (7517): 237–241. Bibcode:2014Natur.513..237X. doi:10.1038/nature13449. ISSN 0028-0836. PMID 24919149.
  73. ^ Gavrilin, Mikhail A.; Mitra, Srabani; Seshadri, Sudarshan; Nateri, Jyotsna; Berhe, Freweine; Hall, Mark W.; Wewers, Mark D. (2009-06-15). "Pyrin Critical to Macrophage IL-1β Response to Francisella Challenge". The Journal of Immunology. 182 (12): 7982–7989. doi:10.4049/jimmunol.0803073. ISSN 0022-1767. PMC 3964683. PMID 19494323.
  74. ^ a b c Downs, Kevin P.; Nguyen, Huyen; Dorfleutner, Andrea; Stehlik, Christian (December 2020). "An overview of the non-canonical inflammasome". Molecular Aspects of Medicine. 76: 100924. doi:10.1016/j.mam.2020.100924. PMC 7808250. PMID 33187725.
  75. ^ Zanoni, Ivan; Tan, Yunhao; Di Gioia, Marco; Springstead, James R.; Kagan, Jonathan C. (October 2017). "By Capturing Inflammatory Lipids Released from Dying Cells, the Receptor CD14 Induces Inflammasome-Dependent Phagocyte Hyperactivation". Immunity. 47 (4): 697–709.e3. doi:10.1016/j.immuni.2017.09.010. PMC 5747599. PMID 29045901.
  76. ^ Chu, Lan H.; Indramohan, Mohanalaxmi; Ratsimandresy, Rojo A.; Gangopadhyay, Anu; Morris, Emily P.; Monack, Denise M.; Dorfleutner, Andrea; Stehlik, Christian (2018-03-08). "The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages". Nature Communications. 9 (1): 996. Bibcode:2018NatCo...9..996C. doi:10.1038/s41467-018-03409-3. ISSN 2041-1723. PMC 5843631. PMID 29520027.
  77. ^ Cahoon, Jason; Yang, Duomeng; Wang, Penghua (September 2022). "The noncanonical inflammasome in health and disease". Infectious Medicine. 1 (3): 208–216. doi:10.1016/j.imj.2022.09.001. PMC 10699704. PMID 38077630.
  78. ^ "ZBP1 links interferon treatment and dangerous inflammatory cell death during COVID-19". www.stjude.org. Retrieved 2024-03-15.
  79. ^ Palazon-Riquelme, Pablo; Lopez-Castejon, Gloria (November 2018). "The inflammasomes, immune guardians at defence barriers". Immunology. 155 (3): 320–330. doi:10.1111/imm.12989. ISSN 0019-2805. PMC 6187212. PMID 30098204.
  80. ^ Samperio Ventayol P, Geiser P, Di Martino ML, Florbrant A, Fattinger SA, Walder N, et al. (April 2021). "Bacterial detection by NAIP/NLRC4 elicits prompt contractions of intestinal epithelial cell layers". Proceedings of the National Academy of Sciences of the United States of America. 118 (16): e2013963118. Bibcode:2021PNAS..11813963S. doi:10.1073/pnas.2013963118. PMC 8072224. PMID 33846244.
  81. ^ Fattinger SA, Geiser P, Samperio Ventayol P, Di Martino ML, Furter M, Felmy B, et al. (May 2021). "Epithelium-autonomous NAIP/NLRC4 prevents TNF-driven inflammatory destruction of the gut epithelial barrier in Salmonella-infected mice". Mucosal Immunology. 14 (3): 615–629. doi:10.1038/s41385-021-00381-y. PMC 8075861. PMID 33731826.
  82. ^ So, Alexander; Busso, Nathalie (October 2014). "The concept of the inflammasome and its rheumatologic implications". Joint Bone Spine. 81 (5): 398–402. doi:10.1016/j.jbspin.2014.02.009. PMID 24703401.
  83. ^ a b Li, Yangxin; Huang, Hui; Liu, Bin; Zhang, Yu; Pan, Xiangbin; Yu, Xi-Yong; Shen, Zhenya; Song, Yao-Hua (2021-07-02). "Inflammasomes as therapeutic targets in human diseases". Signal Transduction and Targeted Therapy. 6 (1): 247. doi:10.1038/s41392-021-00650-z. ISSN 2059-3635. PMC 8249422. PMID 34210954.
  84. ^ Govindarajan, Vaidya; de Rivero Vaccari, Juan Pablo; Keane, Robert W. (December 2020). "Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets". Journal of Neuroinflammation. 17 (1): 260. doi:10.1186/s12974-020-01944-9. ISSN 1742-2094. PMC 7469327. PMID 32878648.
  85. ^ Terlizzi, Michela; Casolaro, Vincenzo; Pinto, Aldo; Sorrentino, Rosalinda (July 2014). "Inflammasome: Cancer's friend or foe?". Pharmacology & Therapeutics. 143 (1): 24–33. doi:10.1016/j.pharmthera.2014.02.002. PMID 24518102.
  86. ^ Karki, Rajendra; Kanneganti, Thirumala-Devi (April 2019). "Diverging inflammasome signals in tumorigenesis and potential targeting". Nature Reviews Cancer. 19 (4): 197–214. doi:10.1038/s41568-019-0123-y. ISSN 1474-175X. PMC 6953422. PMID 30842595.
  87. ^ Karki, Rajendra; Man, Si Ming; Kanneganti, Thirumala-Devi (2017-02-01). "Inflammasomes and Cancer". Cancer Immunology Research. 5 (2): 94–99. doi:10.1158/2326-6066.CIR-16-0269. ISSN 2326-6066. PMC 5593081. PMID 28093447.
  88. ^ Allen, Irving C.; TeKippe, Erin McElvania; Woodford, Rita-Marie T.; Uronis, Joshua M.; Holl, Eda K.; Rogers, Arlin B.; Herfarth, Hans H.; Jobin, Christian; Ting, Jenny P.-Y. (2010-05-10). "The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer". Journal of Experimental Medicine. 207 (5): 1045–1056. doi:10.1084/jem.20100050. ISSN 1540-9538. PMC 2867287. PMID 20385749.
  89. ^ Zaki, Mohammad Hasan; Vogel, Peter; Body-Malapel, Mathilde; Lamkanfi, Mohamed; Kanneganti, Thirumala-Devi (2010-10-15). "IL-18 Production Downstream of the Nlrp3 Inflammasome Confers Protection against Colorectal Tumor Formation". The Journal of Immunology. 185 (8): 4912–4920. doi:10.4049/jimmunol.1002046. ISSN 0022-1767. PMC 3104023. PMID 20855874.
  90. ^ Wilson, Justin E; Petrucelli, Alex S; Chen, Liang; Koblansky, A Alicia; Truax, Agnieszka D; Oyama, Yoshitaka; Rogers, Arlin B; Brickey, W June; Wang, Yuli; Schneider, Monika; Mühlbauer, Marcus; Chou, Wei-Chun; Barker, Brianne R; Jobin, Christian; Allbritton, Nancy L (August 2015). "Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt". Nature Medicine. 21 (8): 906–913. doi:10.1038/nm.3908. ISSN 1078-8956. PMC 4529369. PMID 26107252.
  91. ^ Man, Si Ming; Zhu, Qifan; Zhu, Liqin; Liu, Zhiping; Karki, Rajendra; Malik, Ankit; Sharma, Deepika; Li, Liyuan; Malireddi, R.K. Subbarao; Gurung, Prajwal; Neale, Geoffrey; Olsen, Scott R.; Carter, Robert A.; McGoldrick, Daniel J.; Wu, Gang (July 2015). "Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer". Cell. 162 (1): 45–58. doi:10.1016/j.cell.2015.06.001. PMC 4491002. PMID 26095253.
  92. ^ Hu, Bo; Elinav, Eran; Huber, Samuel; Booth, Carmen J.; Strowig, Till; Jin, Chengcheng; Eisenbarth, Stephanie C.; Flavell, Richard A. (2010-12-14). "Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4". Proceedings of the National Academy of Sciences. 107 (50): 21635–21640. Bibcode:2010PNAS..10721635H. doi:10.1073/pnas.1016814108. ISSN 0027-8424. PMC 3003083. PMID 21118981.
  93. ^ Ph.D, Dr Priyom Bose (2024-01-09). "Infammasomes provide a therapeutic target against human diseases". News-Medical. Retrieved 2024-03-15.
  94. ^ Yao, Jing; Sterling, Keenan; Wang, Zhe; Zhang, Yun; Song, Weihong (2024-01-05). "The role of inflammasomes in human diseases and their potential as therapeutic targets". Signal Transduction and Targeted Therapy. 9 (1): 10. doi:10.1038/s41392-023-01687-y. ISSN 2059-3635. PMC 10766654. PMID 38177104.
  95. ^ Coll, Rebecca C; Robertson, Avril A B; Chae, Jae Jin; Higgins, Sarah C; Muñoz-Planillo, Raúl; Inserra, Marco C; Vetter, Irina; Dungan, Lara S; Monks, Brian G; Stutz, Andrea; Croker, Daniel E; Butler, Mark S; Haneklaus, Moritz; Sutton, Caroline E; Núñez, Gabriel (March 2015). "A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases". Nature Medicine. 21 (3): 248–255. doi:10.1038/nm.3806. ISSN 1078-8956. PMC 4392179. PMID 25686105.
  96. ^ Marino, Dan (2023-04-03). "INFLAMMASOME INHIBITORS - 21st Century Miracle Drugs: Spotlight on Clinical NLRP3 Inflammasome Inhibitors". Drug Development and Delivery. Retrieved 2024-03-15.

Further reading

[edit]
Retrieved from "http://en.wiki.x.io/w/index.php?title=Inflammasome&oldid=1237360418#NLRP3_inflammasome"